申请人:Albany Molecular Research, Inc.
公开号:US20140206696A1
公开(公告)日:2014-07-24
Substituted pyridoindoles for incorporation in pharmaceutical compositions employed in the treatment of various diseases correspond to formula (I)
wherein R
1
is H or optionally substituted alkyl; R
2
, R
3
, R
4
are each independently selected from H, —O-alkyl, —S-alkyl, alkyl, halo, —CF
3
, and —CN; G is —CR
12
R
13
—NR
5
— or —NR
5
—CR
12
R
13
; R
5
is H, optionally substituted alkyl, optionally substituted heterocycle, —C(═O)—R
6
, —C(═O)—O—R
7
, or —C(═O)—NR
19
R
20
; R
6
and R
7
are each optionally substituted alkyl or optionally substituted heterocycle; R
8
, R
9
, R
10
, R
11
, R
12
, R
13
, R
19
and R
20
are each independently selected from H or optionally substituted alkyl; R
14
and R
15
are each independently H or halogen; L is —CH
2
—O—, —CH
2
CH
2
—, —CH═CH— or a bond; and B is aryl or heteroaryl or cycloalkyl; with the proviso that, when L is a direct bond, B cannot be unsubstituted heteroaryl or heteroaryl monosubstituted with fluorine.
用于治疗各种疾病的药物组合物中的取代吡啶吲哚对应于公式(I),其中R1为H或可选取代烷基;R2、R3、R4分别选自H、—O-烷基、—S-烷基、烷基、卤素、—CF3和—CN;G为—CR12R13—NR5—或—NR5—CR12R13;R5为H、可选取代烷基、可选取代杂环、—C(═O)—R6、—C(═O)—O—R7或—C(═O)—NR19R20;R6和R7分别为可选取代烷基或可选取代杂环;R8、R9、R10、R11、R12、R13、R19和R20分别选自H或可选取代烷基;R14和R15各自为H或卤素;L为—CH2—O—、—CH2CH2—、—CH═CH—或一个键;B为芳基或杂芳基或环烷基;但当L为直接键时,B不能是未取代的杂芳基或单取代氟的杂芳基。